Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT05784441Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of C-CAR066 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Janssen Pharmaceutical. Primary endpoints: Occurrence of Adverse Events at 24 months and Recommended Phase 2 dose at 24 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
C-CAR066
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05784441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784441.